Publication: Mediators of glucagon-like peptide 2-induced blood flow: Responses in different vascular sites
| dc.contributor.author | KURTEL, HIZIR | |
| dc.contributor.authors | Deniz, Mustafa; Bozkurt, Ayhan; Kurtel, Hizir | |
| dc.date.accessioned | 2022-03-12T17:32:31Z | |
| dc.date.accessioned | 2026-01-11T19:03:45Z | |
| dc.date.available | 2022-03-12T17:32:31Z | |
| dc.date.issued | 2007 | |
| dc.description.abstract | The aims of the present study were: to characterize the mechanisms of hemodynamic alterations induced by GLP-2, and, to compare the responses elicited in the superior mesenteric artery (SMA) to other vascular beds. Anesthetized rats were infused at the doses of 0.9, 2.3, 4.6 and 9.3 nmol/kg into the jugular vein for 60 min. Blood flow in the various arteries was measured by the ultrasonic transit time technique. Some animals were pretreated with indomethacin (5 mg/kg, ip), L-NAME (9, 18, 36 and 72 mu mol/kg, iv), atropine sulfate (1-2 mg/kg, iv), CCK-1 and CCK-2 receptor antagonists (L-364,718 and L-365,260, 1 mg/kg, iv), exendin (9-39) amide (35 nmol/kg, iv) and lidocaine (74 mu mol/kg, iv) prior to the infusion of GLP-2 (4.6 nmol/kg). In another group, capsaicin was applied either systematically (125 mg/kg, sc) or vagally (1 mg/rat). GLP-2 administration at all doses significantly increased the SMA blood flow throughout the experiments. GLP-2 (4.6 nmol/kg) infusion significantly increased blood flow of inferior mesenteric artery and carotid artery but not in any other vessel measured. Only the pretreatments With L-NAME and lidocaine were ineffective in preventing the GLP-2-induced responses. These results implicate that GLP-2-induced blood flow alterations are most significant in the SMA and are not mediated by prostaglandins, muscarinic, GLP-1 or CCK receptors. Our results also suggest that the stimulatory effect of GLP-2 on SMA blood flow is NO-dependent and mediated via intrinsic, non-cholinergic enteric neurons. (c) 2007 Published by Elsevier B.V | |
| dc.identifier.doi | 10.1016/j.regpep.2007.01.002 | |
| dc.identifier.eissn | 1873-1686 | |
| dc.identifier.issn | 0167-0115 | |
| dc.identifier.pubmed | 17346812 | |
| dc.identifier.uri | https://hdl.handle.net/11424/228608 | |
| dc.identifier.wos | WOS:000247365000002 | |
| dc.language.iso | eng | |
| dc.publisher | ELSEVIER SCIENCE BV | |
| dc.relation.ispartof | REGULATORY PEPTIDES | |
| dc.rights | info:eu-repo/semantics/closedAccess | |
| dc.subject | GLP-2 | |
| dc.subject | blood flow | |
| dc.subject | small intestine | |
| dc.subject | MONOMETHYL-L-ARGININE | |
| dc.subject | NITRIC-OXIDE | |
| dc.subject | SENSORY NEURONS | |
| dc.subject | NERVOUS-SYSTEM | |
| dc.subject | SUBSTANCE-P | |
| dc.subject | ESSENTIAL-HYPERTENSION | |
| dc.subject | EXPERIMENTAL COLITIS | |
| dc.subject | ABSORPTIVE FUNCTION | |
| dc.subject | GUINEA-PIGS | |
| dc.subject | LIDOCAINE | |
| dc.title | Mediators of glucagon-like peptide 2-induced blood flow: Responses in different vascular sites | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 15 | |
| oaire.citation.issue | 1-2 | |
| oaire.citation.startPage | 7 | |
| oaire.citation.title | REGULATORY PEPTIDES | |
| oaire.citation.volume | 142 |
